Consensus Statement
Recently published articles about Consensus Statement
Consensus Statement
Next-Step Treatment Options for Treatment-Resistant Depression
January 21, 2026
Strong consensus emerged for augmentation with second-generation antipsychotics, TMS, and ketamine/esketamine in the base vignette. Preferences shifted to include non-augmentative antidepressants and ECT based on patient characteristics.
Consensus Statement
Developing a Treatment-Resistant Depression Consultation Program, Part II: Assessment
May 7, 2025
Consensus recommendations about the goals of a consultation for treatment-resistant depression include establishing the primary diagnosis and comorbidities, clarifying symptoms, identifying goals, documenting treatment history, identifying treatment barriers, and...
Consensus Statement
Developing a Treatment-Resistant Depression Consultation Program, Part I: Practical and Logistical Considerations
April 28, 2025
Key practical considerations are described, including systems-level and financial issues; equity and access to TRD care for a diverse population; selecting a target population and facilitating referrals; communication between...
Consensus Statement
Synopsis of the VA/DOD Clinical Practice Guideline for Management of Bipolar Disorder
January 13, 2025
This synopsis focuses on clinically relevant recommendations related to identification and management of bipolar disorder, including the acute and maintenance phases of illness.
Recent JCP Articles on Consensus Statement
Recent PCC Articles on Consensus Statement
Featured Consensus Statement Research
Consensus Statement
Screening, Diagnosis, and Treatment of Tardive Dyskinesia
January 28, 2020
Tardive dyskinesia remains a serious complication associated with dopamine receptor blocking agents. In this article, read guidance from experts on best practices for tardive dyskinesia screening, diagnosis, and treatment.
